The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease
Open accessAbstract
This study aimed to evaluate the impact of APOE4 homozygosity on Alzheimer's disease (AD) by examining its clinical, pathological and biomarker changes to see whether APOE4 homozygotes constitute a distinct, genetically determined form of AD. Data from the National Alzheimer's Coordinating Center and five large cohorts with AD biomarkers were analyzed. The analysis included 3,297 individuals for the pathological study and 10,039 for the clinical study. Findings revealed that almost all APOE4 homozygotes exhibited AD pathology and had significantly higher levels of AD biomarkers from age 55 compared to APOE3 homozygotes. By age 65, nearly all had abnormal amyloid levels in cerebrospinal fluid, and 75% had positive amyloid scans, with the prevalence of these markers increasing with age, indicating near-full penetrance of AD biology in APOE4 homozygotes. The age of symptom onset was earlier in APOE4 homozygotes at 65.1, with a narrower 95% prediction interval than APOE3 homozygotes. The predictability of symptom onset and the sequence of biomarker changes in APOE4 homozygotes mirrored those in autosomal dominant AD and Down syndrome. However, in the dementia stage, there were no differences in amyloid or tau positron emission tomography across haplotypes, despite earlier clinical and biomarker changes. The study concludes that APOE4 homozygotes represent a genetic form of AD, suggesting the need for individualized prevention strategies, clinical trials and treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“APOE is a lipoprotein involved in the transport of cholesterol and phospholipids between cells, and allelic variation in the APOE gene is a strong genetic risk factor for AD [16, 44].”
From Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease (2025) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“The isoform variation of the protein is associated with an increased risk of developing AD in the general population [11, 16, 44].”
From Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease (2025) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“APOE4 is the strongest genetic risk factor for AD not only increasing the odds ratio of developing the disease but also lowering the age of onset in a dose-dependent fashion.17, 18”
From ApoE is Secreted as a Lipid Nanoparticle by Mammalian Cells: Implications for Alzheimer’s Disease Pathogenesis (2025) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“APOE4 is the strongest genetic risk factor for AD not only increasing the odds ratio of developing the disease but also lowering the age of onset in a dose-dependent fashion.17, 18”
From ApoE is Secreted as a Lipid Nanoparticle by Mammalian Cells: Implications for Alzheimer’s Disease Pathogenesis (2025) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“APOE4 is the strongest genetic risk factor for AD not only increasing the odds ratio of developing the disease but also lowering the age of onset in a dose-dependent fashion.17, 18”
From ApoE is Secreted as a Lipid Nanoparticle by Mammalian Cells: Implications for Alzheimer’s Disease Pathogenesis (2025) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Although APOEε4 homozygosity may approach 100% penetrance for Aβ deposition in the brain16, even for white or East Asian people, being homozygous for APOEε4 is not synonymous with developing AD dementia”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [16]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“APOE is a lipoprotein involved in the transport of cholesterol and phospholipids between cells, and allelic variation in the APOE gene is a strong genetic risk factor for AD [16, 44].”
From Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease (2025) · cites this paper as [16]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationMontine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
New insights into the genetic etiology of Alzheimer’s disease and related dementias
Bellenguez, C., Küçükali, F., Jansen, I. E., Kleineidam, L., Moreno-Grau, S., Amin, N., Naj, A. C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01024-z · Cited by 2,498
Self-citationPrevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
Self-citationLaMontagne, P. J., Benzinger, T. L., Morris, J. C., Keefe, S., Hornbeck, R., Xiong, C., Grant, E., Hassenstab, J., Moulder, K., Vlassenko, A. G., et al. (2019) · medRxiv · doi:10.1101/2019.12.13.19014902 · Cited by 779
The A4 Study: Stopping AD Before Symptoms Begin?
Sperling, R. A., Rentz, D. M., Johnson, K. A., Karlawish, J. H., Donohue, M., Salmon, D. P., & Aisen, P. S. S. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007941 · Cited by 778
Self-citationAPOE and Alzheimer disease: a major gene with semi-dominant inheritance
Genin, E., Hannequin, D., Wallon, D., Sleegers, K., Hiltunen, M., Combarros, O., Bullido, M. J., Engelborghs, S., De Deyn, P., Berr, C., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.52 · Cited by 714
Research works printed but not linked: 1
- Johnson, S. C. et al. The Wisconsin Registry for Alzheimer’s Prevention: a review of findings and current directions. Alzheimer’s Dement.: Diagnosis, Assess. Dis. Monit. 10, 130–142 (2018).
Cited by
Sorted by citations
Items 101–200 of 368
Xu, C., Liu, J., Guo, M., Wang, J., Bai, X., Zhang, C., Luan, X., Pei, H., Liu, H., Lv, X., et al. (2025) · Research · doi:10.34133/research.0746 · Cited by 8
Wang, H., Dombroski, B. A., Cheng, P., Tucci, A. A., Si, Y., Farrell, J. J., Tzeng, J., Leung, Y. Y., Malamon, J. S., The Alzheimer's Disease Sequencing Project, et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70277 · Cited by 9
Restoring amyloid-β42 and γ-secretase function in Alzheimer’s disease
Espay, A. J., Ezzat, K., Kepp, K. P., Daly, T. P., Robakis, N. K. R. K., Meijer, L., & Imbimbo, B. P. (2025) · Brain · doi:10.1093/brain/awaf294 · Cited by 9
Feldman, H., Villain, N., Frisoni, G. B., & Dubois, B. (2025) · Nature Aging · doi:10.1038/s43587-025-00977-0 · Cited by 8
Thyroid Hormone and Alzheimer Disease: Bridging Epidemiology to Mechanism
Escamilla, S., & Salas-Lucia, F. (2024) · Endocrinology · doi:10.1210/endocr/bqae124 · Cited by 9
Nasal lymphatic obstruction of CSF drainage as a possible cause of Alzheimer’s disease and dementia
Phillips, W. T., & Schwartz, J. G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1482255 · Cited by 8
Falgàs, N., Maure‐Blesa, L., Ances, B. M., Aguilar, L. F., Hartley, S. L., Hassenstab, J. J., Iulita, M. F., Janicki, M. P., Koenig, K. A., Lao, P. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70309 · Cited by 7
Self-citationRodríguez, A., Calero, O., Veiga, S., Menacho-Román, M., Arribas, I., Cano, L., García-Ribas, G., & Calero, M. (2025) · Alzheimer's Research & Therapy · doi:10.1186/s13195-025-01811-w · Cited by 8
Oral diseases as emerging risk factors for Alzheimer’s disease: A scoping review
Yi, Y., Lee, C., Shin, H., & Shin, S. (2025) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2025.11.003 · Cited by 8
Günaydın, C., Hackett, N. R., Wakim, V., Sondhi, D., Kaminsky, S. M., & Crystal, R. G. (2025) · Human Gene Therapy · doi:10.1177/10430342251401888 · Cited by 10
Weber, C. M., Moiz, B., Pena, G. S., Kheradmand, M., Wunderler, B., Kettula, C., Sangha, G. S., Smith, J. C., & Clyne, A. M. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105487 · Cited by 9
Yang, C.-H., Li, C., Sie, Y.-Y., Chen, L., Yuan, Y.-H., & Hou, W. (2024) · Botanical studies · doi:10.1186/s40529-024-00443-x · Cited by 7
Huynh, T. N. T., Fikse, E. N., Torre, A. L. D. L., Havrda, M. C., Chang, C. C. Y., & Chang, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413690 · Cited by 9
Multi-organ imaging-derived polygenic indexes for brain and body healthPreprint
Yang, X., Sullivan, P. F., Li, B., Fan, Z., Ding, D., Shu, J., Guo, Y., Paschou, P., Bao, J., Shen, L., et al. (2023) · medRxiv · doi:10.1101/2023.04.18.23288769 · Cited by 9
APOE genotype and cognitive decline: educational context as a moderator of genetic risk
Walsemann, K. M., Jackson, H. M., Boardman, J. D., & Herd, P. (2025) · The Journals of Gerontology Series B · doi:10.1093/geronb/gbaf110 · Cited by 6
Abdullah, L. B., Zhou, Z., Alliey, N. A., Barber, R. C., Hall, J. R., & O’Bryant, S. E. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1627525 · Cited by 6
Association between dietary fat intake and long-term risk of dementia: a prospective cohort study
Wu, M., Huang, L., Huang, Y.-H., Shen, J., Chen, H., Wang, B., Zong, G., Guasch‐Ferré, M., Rong, S., Liu, X., et al. (2025) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.09.028 · Cited by 6
Huang, X., Huang, L., Tan, C., Wei, J.-M., Zhang, X.-H., Tan, L., & Xu, W. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13434-0 · Cited by 6
APOE ε4 and Accelerated Cognitive Decline Among Cognitively Healthy Middle-Aged and Older Adults
Chung, Y.-C. E., Chung, R.-H., Hsu, C.-C., Liu, Y.-L., Lai, R.-H., Hung, W.-J., Wu, R., Jiang, Y., Chuang, S., Tsai, S. F., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.0853 · Cited by 6
Shah, A. J., Dar, M. Y., Adnan, M., Varma, T., Agarwal, D., Garg, P., Mir, R. H., Meena, R., & Masoodi, M. H. (2025) · Biotechnology Reports · doi:10.1016/j.btre.2025.e00881 · Cited by 7
Survival Differences Between Individuals With Typical and Atypical Phenotypes of Alzheimer Disease
Bader, I., Groot, C., van der Flier, W. M., Pijnenburg, Y. A. L., & Ossenkoppele, R. (2025) · Neurology · doi:10.1212/wnl.0000000000213603 · Cited by 6
Development and validation of polygenic scores for within-family prediction of disease risksPreprint
Moore, S., Davidson, I., Anomaly, J., Li, J. H., Ahangari, M. M., Moissiy, L., Christensen, M., Young, A. I., Stern, D., & Wolfram, T. (2025) · medRxiv · doi:10.1101/2025.08.06.25333145 · Cited by 8
Anderle, S., Bonnar, O., Henderson, J., Shaw, K., Chagas, A. M., McMullan, L., Webber, A., Mcgowan, K., King, S. L., & Hall, C. N. (2025) · Communications Biology · doi:10.1038/s42003-025-07585-z · Cited by 5
Fu, Z., Zhang, W., & Li, S. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1591705 · Cited by 6
Tau biology, biomarkers, and therapeutics
Frost, B. E., Kolb, H. C., Algeciras‐Schimnich, A., Betthauser, T. J., DeVos, S. L., Edelmayer, R. M., Elwood, F., Fleisher, A., Henley, D. B., Horie, K., et al. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70165 · Cited by 7
Self-citationXiong, C., Tang, Y., Chen, J., Fan, M., Wei, L., Dong, Z., Lai, X., Men, X., Chen, Q., Li, D., et al. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00512-6 · Cited by 6
Multidomain therapy for Alzheimer’s disease: a scoping review of cognitive decline trials
Roach, J. C., Glusman, G., Rapozo, M. K., Merrill, D. A., Bramen, J. E., Hodes, J. F., Siddarth, P., Meysami, S., Elhelou, S. H. K., Glatt, R. M., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00912-2 · Cited by 6
Biomarker-integrated prognostic stagings for Alzheimer’s Disease
Shin, D., Lee, S., Kim, J. P., Jang, H., Yun, J., Chun, M. Y., Ahn, J., Kim, S., Kim, K., Yoon, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68732-6 · Cited by 5
Tian, X., Li, H., Lin, H., Li, C., Wang, Y.-P., Bai, H. X., Lan, W., & Liu, J. (2025) · Neural Networks · doi:10.1016/j.neunet.2025.107343 · Cited by 5
Campagna, J. J., Chandra, S., Teter, B., Cohn, W., Pham, J. D., Kim, Y.-S., Jagodzinska, B. M., Vadivel, K., Alam, P., Bilousova, T. V., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-96131-2 · Cited by 7
Ca2+/calmodulin signaling in organismal aging and cellular senescence: Impact on human diseases
Berchtold, M. W., & Villalobo, A. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167583 · Cited by 7
Wu, J., Wang, J., Xiao, Z., Lu, J., Ma, X., Zhou, X., Wu, Y., Liang, X., Zheng, L., Ding, D., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcaf015 · Cited by 6
Wang, Y., Li, F., Qin, Q., Li, T., Wang, Q., Li, Y., Li, Y. H., & Jia, J. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100065 · Cited by 6
Trompeta, C., Gasca‐Salas, C., Rodríguez‐Rojas, R., Fernández‐Rodríguez, B., Clarimón, J., García‐Cañamaque, L., Guida, P., Hernández‐Fernández, F., Sánchez‐Juan, P., Olazarán, J., et al. (2025) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2025.123510 · Cited by 6
Reply to: Challenges to identifying risk versus protective factors in Alzheimer’s disease
Fortea, J., Vaqué‐Alcázar, L., Pegueroles, J., Alcolea, D. A., Belbin, O., Dols‐Icardo, O., Videla, L., Gispert, J. D., Suárez‐Calvet, M., Johnson, S. C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03159-4 · Cited by 5
Self-citationPhoton-counting micro-CT scanner for deep learning-enabled small animal perfusion imaging
Allphin, A. J., Nadkarni, R., Clark, D. P., & Badea, C. T. (2025) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ade94b · Cited by 4
König, T., Silvaieh, S., Parvizi, T., Wurm, R., Goeschl, S., Uhlik, E., Farr, C. V., Berger–Sieczkowski, E., Untersteiner, H., Zimprich, A. A., et al. (2025) · Genetics in Medicine · doi:10.1016/j.gim.2025.101517 · Cited by 4
Sagar, R., Huang, Y., Dong, D., Boyd, R. J., Ahmed, W., Witwer, K. W., & Mahairaki, V. (2025) · Journal of Extracellular Biology · doi:10.1002/jex2.70074 · Cited by 4
Kynigopoulos, D., Fella, E., Shahabian, L., Christodoulou, C. C., Papacharalampous, R., Diskos, K., Vagiaki, L. E., Sidiropoulou, K., Pipis, M., Kleopa, K. A., et al. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1636624 · Cited by 4
Weber, D. M., Stroh, M. A., Taylor, S. W., LAGIER, R. J., Louie, J. Z., Clarke, N. J., Vaillancourt, D. E., Rayaprolu, S., Duara, R., & Racke, M. K. (2025) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200546 · Cited by 4
Advances in plasma biomarkers for the diagnosis of Alzheimer’s disease
Wu, H., Liu, L., & Zeng, L. (2026) · Brain Research · doi:10.1016/j.brainres.2025.150138 · Cited by 4
Rajendrakumar, A. L., Arbeev, K. G., Bagley, O., Duan, M., Yashin, A. I., Ukraintseva, S. V., & Initiative, A. D. N. (2025) · PLoS ONE · doi:10.1371/journal.pone.0316808 · Cited by 4
Russo, M., Nardini, D., Melchiorre, S., Ciprietti, C., Polito, G., Punzi, M., Dono, F., Santilli, M., Thomas, A., Sensi, S. L., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14398 · Cited by 5
Predictors of Bi-directional Transitions From Mild Cognitive Impairment in a Diverse Cohort
Gonzales, M. M., Fernandez, R. A., Kremen, S. A., Tan, Z. S., Werry, A. E., Jian, X., Hart, J., Royall, D. R., Maestre, G. E., Espinoza, S. E., et al. (2025) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaf041 · Cited by 4
Zhu, N., Altuna, M., Arranz, J., Rodríguez‐Baz, Í., Sánchez‐Saudinós, M. B., Videla, L., Valldeneu, S., Carrera-Vega, M., Romero, S., Fortea, J., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf437 · Cited by 5
Self-citationAPOE4 Increases Susceptibility to Amyloid, Accelerating Episodic Memory DeclinePreprint
Vanderlip, C. R., Stark, C. E. L., & Initiative, T. A. D. N. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.23.630203 · Cited by 4
Reply: PART and amyloid cascade hypotheses are alive and well (but are not so simple)
Braak, H., & Tredici, K. D. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02921-3 · Cited by 4
Neurodegenerative diseases need more mechanism-informed trials
(2026) · Nature Medicine · doi:10.1038/s41591-026-04258-0 · Cited by 4
Li, W., Fan, D., Sun, Q., Wang, L., Huang, B., Yu, Z., Tian, D., Shen, Y., Tan, C., Zeng, G., et al. (2025) · Aging Cell · doi:10.1111/acel.70036 · Cited by 3
The associations of cerebrospinal fluid ApoE and C1q with Alzheimer's disease biomarkers
Lin, Y.-J., Liu, Y., Sheng, Z.-H., Fu, Y., Ma, L.-Z., Zhang, Z.-H., Wang, L.-Y., Huang, L.-Y., Liu, M., Wang, Z.-T., et al. (2025) · Journal of Alzheimer’s Disease · doi:10.1177/13872877251320419 · Cited by 3
Cholesterol-modifying strategies for Alzheimer disease: promise or fallacy?
Azarfar, K., Decourt, B., Camacho, B. S., Lawrence, J. J., Omondi, T. R., & Sabbagh, M. N. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2483928 · Cited by 3
Dieter, F., Jacobs, K., Quentin, A., Prvulovic, D., Reif, A., Pantel, J., Pilatus, U., Hattingen, E., Matura, S., & Eckert, G. P. (2025) · GeroScience · doi:10.1007/s11357-025-01813-4 · Cited by 5
Athanasaki, A., Tsantzali, I., Theodorou, A., Michalopoulou, A., Constantinides, V. C., Boufidou, F., Tzartos, J. S., Tsalouchidou, P., Zompola, C., Paraskevas, S. G., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199531 · Cited by 3
Petek, B., Mo, M., Xu, H., Norgren, J., Hoang, M. T., Villa‐Lopez, M., Häbel, H., Kele, J., Naia, L., Maioli, S., et al. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251385903 · Cited by 3
Hang, Z., Bian, X., Cai, S., Zhou, L., Wen, Y., & Du, H. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114644 · Cited by 3
Yang, N. V., Wang, S., Li, B., Simms, J. A., Dinh, L., Huang, A., Oei, J. H., Yassine, H. N., & Krauss, R. M. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71306 · Cited by 3
Magavern, E. F., Deshmukh, H., Asselin, G., Theusch, E., Trompet, S., Li, X., Noordam, R., Chen, Y. I., Seeman, T. E., Taylor, K. D., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2024.107575 · Cited by 3
Gao, X., Yin, Y., Chen, Y., Lu, L., Zhao, J., Xu, L., Wu, J., Li, Q., & Zeng, R. (2025) · Cell Genomics · doi:10.1016/j.xgen.2025.100763 · Cited by 3
Brain health clinics – An evolving clinical pathway?
Butters, A. F., Blackman, J., Farouk, H., Meky, S., Newson, M., Lemke, T., Rosewell, N., Selwood, J., Turner, N. L., Coulthard, E. J., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100051 · Cited by 5
Wang, Y., Liu, H., Ye, Y., Fang, W., Lin, A., Dai, X., Ye, Q., Chen, X., & Zhang, J. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02093-3 · Cited by 4
Teipel, S. J., Tang, Y., & Khachaturian, A. S. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70083 · Cited by 3
Associations of the LIBRA index with cognitive resilience to genetic susceptibility to dementia
Wagner, M., Neuffer, J., Grand, Q. L., Mishra, A., Berr, C., Debette, S., Helmer, C., Proust‐Lima, C., & Samieri, C. (2025) · American Journal of Epidemiology · doi:10.1093/aje/kwaf108 · Cited by 3
Mukesha, D., Sarter, M., Dubray, M., Durand, F., Boutillier, S., Pham-Van, L. D., Halter, D., Kul, S., Blanc, F., Gurvit, H. I., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251378653 · Cited by 3
O’Connor, A., Ryan, N. S., Belder, C. R. S., Lynch, D. S., Lahiri, N., Houlden, H., Rohrer, J. D., Fox, N. C., & O’Dowd, S. (2024) · Practical Neurology · doi:10.1136/pn-2024-004241 · Cited by 4
Vicidomini, C., Goode, T. D., McAvoy, K. M., Yu, R., Beveridge, C. H., Iyer, S. N., Victor, M. B., Leary, N., Evans, L., Steinbaugh, M. J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.26.605338 · Cited by 4
Hernandez Arriaza, R., Reil, D., Fatuzzo, N., Fu, M., Dai, Y., Fernandez Martinez, D., Jiang, H., Holtzman, D. M., Greicius, M. D., & Khosla, C. (2025) · Biochemistry · doi:10.1021/acs.biochem.5c00503 · Cited by 2
Direct-to-Consumer Testing: Benefits and Concerns of Commercially Accessed Laboratory Tests
Orth, M., Sandberg, S., & Shih, P. (2025) · Clinical Chemistry · doi:10.1093/clinchem/hvaf004 · Cited by 3
Itoh, K., Kuwabara, A., Otsuka, R., Sugimoto, T., Sakurai, T., Niida, S., Ao, M., Tanaka, K., Takenaka, S., & Kanouchi, H. (2025) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.24-233 · Cited by 2
Farina, F. R., Bennett, M., Grill, J. D., Sperling, R. A., LAWLOR, B. A., & Griffith, J. W. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70225 · Cited by 2
Self-citationCarlisle, T. C., Bateman, J. R., Yang, Y., Lachner, C., Stockbridge, M. D., Flashman, L. A., Chemali, Z. N., Alzbeidi, N., Pressman, P., Osibajo, A.-M., et al. (2025) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.20240203 · Cited by 2
Vanderlip, C. R., & Stark, C. E. L. (2025) · Neurology · doi:10.1212/wnl.0000000000213853 · Cited by 2
Mantovani, D. B. D. A., Oliveira, L. C., Spelta, L. E. W., Carvalho, C. L., Forlenza, O. V., Marie, S. K. N., Buchpiguel, C. A., Coutinho, A. M., & Faria, D. D. P. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70449 · Cited by 2
Li, L., Wang, W., Li, W., Chen, Y., Mao, Y., Li, Y., & Qiu, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-08958-4 · Cited by 2
Essenburg, C., & Ramanathan, M. K. (2025) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-025-09996-1 · Cited by 2
Nazareth, M., Duck, S. A., Fassinger, A., Elmore, G., Pinto, C., Nugent, M., Pierre, M. S., Lechner, C., Jantzie, L. L., Northington, F. J., et al. (2025) · Developmental Neuroscience · doi:10.1159/000548432 · Cited by 2
Lehodey, A., Montagne, B., Rehel, S., Kaliman, P., Chocat, A., Mézenge, F., Landeau, B., Sayette, V. D. L., Chételat, G., Rauchs, G., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01923-3 · Cited by 3
Wang, M., Niu, D., Zhang, Q., Tang, Y., Zhao, Y., & Chen, F. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.151352 · Cited by 2
Meyer, C. C., de Mattos, E. P., Burger, R. M., Blumenstock, G., Sena, P. P., Gordon, C. R., Zaltzman, R., França, M. C., Pereira, M. L. S., Cornejo‐Olivas, M., et al. (2026) · Human Molecular Genetics · doi:10.1093/hmg/ddag016 · Cited by 2
Synapse-associated neuropathological markers in Alzheimer's disease
Barrantes, F. J. (2026) · Brain · doi:10.1093/brain/awag117 · Cited by 2
Advancing Precision Dementia Care With Genetic-Exposome Risk Assessment
Andrews, S. J., & Yaffe, K. S. (2026) · JAMA Neurology · doi:10.1001/jamaneurol.2026.0573 · Cited by 2
Buntanetap treatment in mild to moderate Alzheimer’s disease: phase 2/3 study
Fang, C., Feng, D., Gaines, M., Laskowitz, D., Sanders, L. H., Liow, K. K., Peckham, E. L., Ritter, A., Chen, M., Morin, A., et al. (2026) · npj Dementia · doi:10.1038/s44400-026-00073-z · Cited by 2
Morozova, I., Zorkina, Y., Berdalin, A. B., Ikonnikova, A. Y., Emelyanova, M., Fedoseeva, E., Antonova, O., Gryadunov, D. A., Andryushchenko, A. V., Ushakova, V. M., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14171883 · Cited by 3
Ciurleo, G. C. V., de Azevedo, O. G. R., Carvalho, C. G. M., Vitek, M. P., Warren, C. A., Guerrant, R. L., & Oriá, R. B. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.09.004 · Cited by 2
The Effect of FTY720 on Sphingolipid Imbalance and Cognitive Decline in Aged EFAD Mice
Luo, Q., Crivelli, S. M., Zong, S., Giovagnoni, C., van Kruining, D., Mané-Damas, M., den Hoedt, S., Berkeš, D., de Vries, H. E., Mulder, M. T., et al. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230053 · Cited by 3
Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemia
Ronnacker, J., Grau, M., Klasmeier, M., Klesse, C., Baldauf, H., Abert, S., Berdel, A. F., Füsser, F. T., Sandmann, S., Albring, J. C., et al. (2025) · Blood · doi:10.1182/blood.2024026886 · Cited by 3
Khaled, M., Al-Jamal, H., Matar, D. B., Ibrahim, A., Tajer, L., Issa, N., El-Mir, R., & Hantour, J. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877241307307 · Cited by 2
Whole-genome sequencing reveals the impact of lipid pathway and APOE genotype on brain amyloidosis
Patel, M., Pottier, C. P., Fan, K.-H., Cetin, A., Johnson, M., Ali, M., Liu, M., Gorijala, P., Budde, J., Shi, R., et al. (2025) · Human Molecular Genetics · doi:10.1093/hmg/ddaf017 · Cited by 2
Valle‐Tamayo, N., Aranha, M. R., Pérez‐González, R., Serrano‐Requena, S., Videla, L., Barroeta, I., Benejam, B., Chiva‐Blanch, G., Jiménez, A., Busciglio, J. A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70137 · Cited by 2
Self-citationVanherle, S., Janssen, A., de Ravé, M. G., Janssen, B., Lodder, C., Lucena, P. B., Kessels, S., Hardy, J., Vandeput, E., Wang, Y., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03036-7 · Cited by 4
Zhang, H., Zhang, J., Hsu, C. L., Hui, E. S. K., Tse, K., Mak, H. K., & Shum, D. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf278 · Cited by 2
Estanga, A., Elorriaga, I. T., Ecay‐Torres, M., Condado, J. G., García‐Sebastián, M., de Arriba, M., López, C., Ros, N., Iriondo, A., Reparaz‐Escudero, I., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14228176 · Cited by 2
Whitman, E. T., Elliott, M. L., Knodt, A. R., Abraham, W. C., Anderson, T., Cutfield, N. J., Hogan, S., Ireland, D. R., Melzer, T. R., Ramrakha, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.19.608305 · Cited by 2
APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-betaPreprint
Cicognola, C., Salvadó, G., Smith, R. A., Palmqvist, S., Stomrud, E., Betthauser, T. J., Johnson, S. C., Janelidze, S., Mattsson, N., Hansson, O., et al. (2024) · medRxiv · doi:10.1101/2024.09.20.24314064 · Cited by 2
Self-citationHuynh, T. N. T., Fikse, E. N., Havrda, M. C., Chang, C. C. Y., & Chang, T. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.24.620063 · Cited by 2
Ramaswamy, V. G., Ahirwar, M., Ryan, G., Dugger, B. N., Al‐Dalahmah, O., Signaevsky, M., Purohit, D. P., Haroutunian, V. H., & Finkbeiner, S. M. (2025) · medRxiv · doi:10.1101/2025.02.03.25321603 · Cited by 2
Yılmaz, E., Chen, K. W., Cakir, E. Ö., Bhattarai, P., Liu, M., Ciener, B., Qiao, M., Lantigua, R., Medrano, M. Z., Rivera, D., et al. (2025) · medRxiv · doi:10.1101/2025.05.21.25328040 · Cited by 4
Deecke, L., Ohlei, O., Goldeck, D., Homann, J., Toepfer, S., Demuth, I., Bertram, L., Pawelec, G., & Lill, C. M. (2025) · Cells · doi:10.3390/cells14040250 · Cited by 1
Mahley, R. W. (2025) · Springer eBooks · doi:10.1007/978-3-031-52641-1_2-1 · Cited by 1
Kaishima, M., Ito, J., Takahashi, K., Tai, K., Kuromitsu, J., Bun, S., & Ito, D. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01754-2 · Cited by 1
Perceptual discrimination of complex objects: Apolipoprotein E e4 gene‐dose effects in mid‐life
Lancaster, C. L., Berens, S. C., Daly, J., Rusted, J. M., & Bird, C. M. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70246 · Cited by 2
Metadata
- Authors
- Fortea, J., Pegueroles, J., Alcolea, D., Belbin, O., Dols-Icardo, O., Vaqué-Alcázar, L., Videla, L., Gispert, J. D., Suárez-Calvet, M., Johnson, S. C., Sperling, R., Bejanin, A., Lleó, A., & Montal, V.
- Affiliations
- Hospital de Sant Pau (ES)
- Universitat Pompeu Fabra (ES)
- University of Wisconsin–Madison (US)
- Brigham and Women's Hospital (US)
- Barcelona Supercomputing Center (ES)
- Corresponding author
- Fortea, Juan
- Montal, Víctor
- ORCID
- Venue
- Nature Medicine
- Published
- 2024-05
- Volume
- 30
- Issue
- 5
- Pages
- 1284-1291
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC13310155
- OpenAlex
- W4396673676
- Cited by
- 369
- References
- 32
- Citations by year
- 2026: 110 · 2025: 191 · 2024: 67
- FWCI
- 104.73
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-06-17)
- Open access
- Licence
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Funders
- U.S. Department of Health and Human Services (U54HD090256, P01AG036694 and P50AG005134, R21 AG056974, R01 AG027161, S10 OD025245, UF1AG051216, P50 AG033514, and P30 AG062715, UL1 TR002373, P30 AG062715, R01 AG061566, R01 AG054059, R01 AG037639)
- Alzheimer's Association (AARG-22-923680)
- European Commission (948677 and 847648, H2020-SC1-BHC-2018-2020, Grant 2021)
- Generalitat de Catalunya (SLT006/17/00119, SLT002/16/00408)
- Ministerio de Economía y Competitividad (PI22/00307, PI20/01330, PI20/01473, PI18/00435, PI22/00456)
- Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona (LCF/PR/GN17/50300004)
- National Institutes of Health (5u01ag024904-10, 1s10od025245-01, UL1TR002373)
- National Institute on Aging (U01-AG-024904, R01AG081394, UF1AG051216, RF1AG056850, R61AG066543, R01AG037639, R01AG063689, P50AG033514, RF1AG061566, P50AG005134, R21AG056974, R01AG021155, R01AG027161, U24AG057437, P01AG036694, R01AG054059, P30AG062715, U24AG072122)
- National Center for Advancing Translational Sciences
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54HD090256)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- Alzheimer's disease, APOE3, amyloid PET, cerebrospinal fluid amyloid, tau PET, symptom onset age, disease progression, autosomal dominant Alzheimer's disease, Down syndrome, penetrance, dementia stages
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Apolipoproteins E, Female, Homozygote, Humans, Male, Middle Aged, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Age of Onset, Positron-Emission Tomography, Apolipoprotein E3, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
